- Prevention trials in Alzheimer disease: one step forward?J Touchon
Neurology Service, Guy de Chauliac Hospital, Montpellier, France
Neurology 67:S21-2. 2006..A critical concern is the benefit and relative risk of giving a treatment to non-demented patients or to asymptomatic subjects. Some trials are under way and will perhaps move the field of prevention of dementia one big step forward...
- Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathologyJacques Touchon
CHU, INSERM 361, Montpellier, France
Curr Med Res Opin 22:49-59. 2006..This retrospective analysis investigated whether AD patients with and without symptoms suggesting concomitant Lewy body pathology demonstrated different responses to therapy...
- Functional Vitamin E deficiency in ApoE4 patients with Alzheimer's diseaseEmilie Mas
Department of Biochemistry, Lapeyronie Hospital, Montpellier, France
Dement Geriatr Cogn Disord 21:198-204. 2006..Our study strongly supports the hypothesis of an impairment of lipophilic antioxidant delivery to neuronal cells in AD leading to a tissular antioxidant deficiency which could facilitate oxidative stress...
- [Oestro-progestagen treatment combined with rivastigmine in menopausal women suffering from Alzheimer's disease. The results of a 28-weeks controlled study]Anne Sophie Rigaud
Departement de Geriatrie, Service du Pr F Forette, Hopital Broca, Paris
Presse Med 32:1649-54. 2003..To compare the efficacy on cognitive function of the combination of hormone replacement therapy with rivastigmine, acetylcholinesterase inhibitor, in menopausal women suffering from mild to moderately severe Alzheimer's disease...
- Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year periodRoger Bullock
Kingshill Research Centre, Victoria Hospital, Swindon, UK
Curr Med Res Opin 21:1317-27. 2005....
- Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's diseaseRoger Bullock
Kingshill Research Centre, Swindon, UK
Curr Med Res Opin 22:483-94. 2006..This retrospective analysis investigated whether younger and older patients showed differential tolerability and efficacy responses to cholinesterase inhibitor treatment...
- Diagnostic value of event-related evoked potentials N200 and P300 subcomponents in early diagnosis of Alzheimer's disease and mild cognitive impairmentKarim Bennys
Department of Neurology, University Hospital of Montpellier, France
J Clin Neurophysiol 24:405-12. 2007..The abnormalities of N2 and P3 components may be linked, in AD and MCI, to an alteration of automatic and controlled attention processing...
- [Mild cognitive impairment]Jacques Touchon
Service de Neurologie, CM2R du Languedoc Roussillon, Inserm E 361, CHU, Montpellier Cedex 05
Presse Med 36:1464-8. 2007..Biological and radiological markers will provide greater and more systematic support for diagnosis in the near future, particularly for early detection of Alzheimer's disease...
- Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's diseaseKathy Dujardin
Neurology and Movement Disorders Unit, Faculty of Medicine and Lille University Hospital, EA2683, Lille, France
J Neurol 253:1154-9. 2006....
- Mild extrapyramidal signs and functional impairment in ageingMarcus Richards
MRC National Survey of Health and Development, University College London, UK
Int J Geriatr Psychiatry 17:150-3. 2002..Little is known about the clinical significance of mild extrapyramidal signs (EPS) in elderly individuals. We investigated whether EPS are associated with functional impairment in older people with cognitive decline...
- Mild cognitive impairment: a nosological entity?Thierry Voisin
Department of Internal Medicine and Clinical Gerontology, Acute Unit for Alzheimer s Patients, Toulouse University, Toulouse, France
Curr Opin Neurol 16:S43-5. 2003..Future research should be focussed on redefining the criteria of the mild cognitive impairment entity. This could enable the better development of appropriate therapeutic interventions...
- Text structure and content modulate the recall of patients with dementia of the Alzheimer's typeMarie Christine Gely-Nargeot
Laboratoire de Psychologie Expérimentale et Cognitive, Université Montpellier III, Canada
Brain Cogn 48:371-5. 2002..Results are discussed with reference to the influence of text structure and the situation model on text recall...
- Pathogenic theories and intrathecal analysis of the sporadic form of Alzheimer's diseaseFrançois Torreilles
CNRS UMR 5094, Institut de Biotechnologie et Pharmacologie, UFR Pharmacie, 15 Avenue Charles Flahault, 34093 Montpellier Cedex 5, France
Prog Neurobiol 66:191-203. 2002..The present review analyzes the main results of intrathecal content analyses in light of pathogenic theories proposed to explain the damage associated with AD and observed in the brain of patients by postmortem examination...
- [Prototypic value of semantic intrusion errors in Alzheimer's disease]Marianne Canolle
Hopital Corentin Celton, Issy les Moulineaux, France
Psychol Neuropsychiatr Vieil 6:67-79. 2008..In conclusion, the qualitative analysis of the prototypic value of intrusion errors in Alzheimers opens up new clinical and methodological considerations...